| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3851291 | American Journal of Kidney Diseases | 2007 | 12 Pages |
Abstract
The high future cost of hemodialysis constrains incremental cost-effectiveness ratios to values greater than commonly cited thresholds ($50,000/QALY). Based on available evidence, warfarin appears to be the optimal therapy to prevent thromboembolic stroke in hemodialysis patients with atrial fibrillation. Additional study is required to determine the efficacy of warfarin and risk of bleeding complications in this population so that patients can make a more informed choice.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Robert R. MD, FRCPC, David M.J. MD, MSc, FRCPC, Matthew J. MD, MHS, FRCPC, Ahmed M. MD, MSc, FRCPC,